Market Place
Sourcing Support
Zealand Pharma Provides Update On Dasiglucagon In CHI
09 Oct 2024 //
GLOBENEWSWIRE
Zealand`s Dasiglucagon Severe Hypoglycemia Med Gets CHMP Nod
31 May 2024 //
GLOBENEWSWIRE
Zealand says US FDA turns down drug for low blood sugar in infants
21 Dec 2023 //
REUTERS
Zealand announces designation of priority review by the US FDA for dasiglucagon
30 Aug 2023 //
GLOBENEWSWIRE
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon
30 Jun 2023 //
GLOBENEWSWIRE
Zealand Pharma Submits MAA for Dasiglucagon
26 Jun 2023 //
GLOBENEWSWIRE
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon
20 Sep 2022 //
GLOBENEWSWIRE
Zealand Presents Data from Ph3 Trial Dasiglucagon Congenital Hyperinsulinism
19 Sep 2022 //
GLOBENEWSWIRE
Zealand Pharma Announces License & Agreement with Novo Nordisk for ZEGALOGUE
08 Sep 2022 //
GLOBENEWSWIRE
Zealand Announces Global License and Development Agreement with Novo Nordisk
07 Sep 2022 //
GLOBENEWSWIRE
Zealand Pharma reports positive PIII results against congenital hyperinsulinism
19 May 2022 //
MEDWATCH
Advancement of Clinical Pipeline; Key Data for Glepaglutide and Dasiglucagon
11 Mar 2022 //
GLOBENEWSWIRE
Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE injection
24 Jun 2021 //
GLOBENEWSWIRE
Zealand announces data from the first pH3-trial with dasiglucagon in (CHI)
15 Dec 2020 //
GLOBENEWSWIRE
Zealand presents clinical and non-clinical evidence for dasiglucagon
14 Jun 2020 //
GLOBENEWSWIRE
Hypoglycemia `Epipen` clears Phase III, hurtles toward FDA decision
24 Sep 2019 //
ENDPTS
Zealand`s Dasiglucagon Hits the Mark in Phase III Pediatric Hypoglycemia Trial
24 Sep 2019 //
BIOSPACE
Zealand`s reports completion of the IInd & pivotal Ph3 trial with dasiglucagon
29 May 2018 //
NASDAQ
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.